Investment Thesis
Apimeds is a pre-revenue pharmaceutical company with severe cash burn and negative profitability. The company is hemorrhaging cash at -$5.1M operating cash flow with only $7.0M in reserves, creating critical runway concerns. Without demonstrated commercial traction or clear path to profitability, the company faces existential funding risk.
Strengths
- Strong current ratio of 8.34x provides near-term liquidity buffer
- Zero debt burden eliminates solvency pressure from leverage
- Stockholders equity of $8.2M provides some balance sheet cushion
Risks
- Pre-revenue model with no commercial product sales indicates zero market validation
- Operating cash burn of -$5.1M with only ~1.4 years of cash runway at current burn rate
- Negative ROE of -59.4% and ROA of -52.4% indicate severe value destruction
- No insider trading activity in 90 days suggests lack of insider confidence
- Development-stage pharmaceutical with unproven product-market fit and regulatory approval uncertainty
Key Metrics to Watch
- Monthly cash burn rate and runway duration
- Progress toward revenue generation or regulatory milestones
- Changes in operating cash flow trajectory
- Debt issuance or equity dilution financing activity
- Clinical trial progress and FDA approval status
Financial Metrics
Revenue
N/A
Net Income
-4.8M
EPS (Diluted)
$-0.47
Free Cash Flow
-5.1M
Total Assets
9.3M
Cash
7.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-59.4%
ROA
-52.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.34x
Quick Ratio
8.34x
Debt/Equity
0.00x
Debt/Assets
11.8%
Interest Coverage
-1,580.96x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T01:48:10.316703 |
Data as of: 2025-09-30 |
Powered by Claude AI